IGF-1 LR3: FDA Status and Evidence
A long-acting research analog of IGF-1 with no FDA-approved form. It has no human clinical-trial evidence; the approved IGF-1 drug is a different molecule.
Medically reviewed by Charles Kamen, MD, board-certified neurologist ·
What the research shows
IGF-1 LR3 is a modified form of IGF-1 made to last longer in the body. It is used in laboratory research. There are no human clinical trials. The approved IGF-1 drug, mecasermin, is prescribed only for severe primary IGF-1 deficiency and carries warnings for low blood sugar.
It is on the World Anti-Doping Agency prohibited list.
Frequently Asked Questions
Is IGF-1 LR3 FDA-approved?
No. Only mecasermin, a different IGF-1 product, is FDA-approved, and only for severe primary IGF-1 deficiency.
Can a pharmacy compound IGF-1 LR3?
It is not on FDA's bulk-substance lists for compounding.
Has IGF-1 LR3 been tested in humans?
No human clinical trials have been published.
Related Growth hormone support
Sermorelin
A growth-hormone-releasing peptide studied for energy, body composition, and recovery - physician-supervised in Las Vegas.
CJC-1295 & Ipamorelin
A commonly paired GHRH/GHRP peptide combination studied for recovery and body composition - physician-supervised in Las Vegas.
MK-677 (Ibutamoren)
An oral growth hormone secretagogue studied for appetite, sleep, and body composition - physician-supervised in Las Vegas.
Tesamorelin
A GHRH analog studied for visceral fat and body composition - physician-supervised in Las Vegas.